Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).
- DOI
- 10.1186/1741-7015-11-59
- Published
- 2013 Mar 4
- Container
- BMC medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/1741-7015-11-59,
title = {Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).},
author = {Bruera G and Cannita K and Di Giacomo D and Lamy A and Frébourg T and Sabourin JC and Tosi M and Alesse E and Ficorella C and Ricevuto E},
year = {2013},
journal = {BMC medicine},
doi = {10.1186/1741-7015-11-59},
url = {https://doi.org/10.1186/1741-7015-11-59}
}RIS
TY - JOUR TI - Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). AU - Bruera G AU - Cannita K AU - Di Giacomo D AU - Lamy A AU - Frébourg T AU - Sabourin JC AU - Tosi M AU - Alesse E AU - Ficorella C AU - Ricevuto E PY - 2013 JO - BMC medicine DO - 10.1186/1741-7015-11-59 UR - https://doi.org/10.1186/1741-7015-11-59 ER -
APA
G, B., K, C., D, D. G., A, L., T, F., JC, S., M, T., E, A., C, F., & E, R. (2013). Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).. BMC medicine. https://doi.org/10.1186/1741-7015-11-59